UCB SA - Company Profile
Powered by 
All the data and insights you need on UCB SA in one report.
$295
- Save hours of research time and resources with
our up-to-date UCB SA Strategy Report
- Understand UCB SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
UCB SA (UCB) is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company's marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, Germany, Italy, Spain, France, China, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Brussels-Capital Region, Belgium.
Headquarters
Belgium
Address
Allee De La Recherche, 60, Anderlecht, 1070
Website
www.ucb.com
Telephone
32 2 5599999
No of Employees
9,083
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
UCB (EBR)
Revenue (2022)
$5.7B
-4.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-17.9%
(2022 vs 2021)
Market Cap*
$25.0B
Net Profit Margin (2022)
XYZ
-13.9%
(2022 vs 2021)
* As of and is in US$
UCB SA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Product Indications: | Cimzia |
| Neurology: | Vimpat |
| Epilepsy | Keppra |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Financing Agreements | In January, the company invested in IMIDomics. |
| 2023 | New Products/Services | In December, the company unveiled its extensive program of 29 studies. |
| 2023 | Regulatory Approval | In December, the company's BIMZELX (bimekizumab) was approved by the Japanese Ministry of Health, Labour and Welfare to treat adults with psoriatic arthritis, non-radiographic axSpA and ankylosing spondylitis. |
Competitor Comparison
| Key Parameters | UCB SA | Johnson & Johnson | Novartis AG | AstraZeneca Plc | GSK plc |
|---|---|---|---|---|---|
| Headquarters | Belgium | United States of America | Switzerland | United Kingdom | United Kingdom |
| City | Anderlecht | New Brunswick | Basel | Cambridge | Brentford |
| State/Province | - | New Jersey | - | England | England |
| No. of Employees | 9,083 | 131,900 | 76,057 | 89,900 | 70,212 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jonathan Peacock | Chairman | Executive Board | 2023 | 65 |
| Fiona du Monceau | Vice Chairwoman | Executive Board | 2022 | 45 |
| Jean-Christophe Tellier | Chief Executive Officer | Senior Management | 2014 | 64 |
| Sandrine Dufour | Executive Vice President; Chief Financial Officer | Senior Management | 2020 | 57 |
| Iris Low-Friedrich, M.D. | Chief Medical Officer; Executive Vice President - Global Projects and Development | Senior Management | 2008 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward